Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial

Mechanisms accounting for sex differences in the incidence of adverse events caused by fluoropyrimidine treatments, and histologic differences in efficacy are insufficiently understood. We determined differences between the sexes in terms of the safety of S-1 plus oxaliplatin (SOX)/bevacizumab-versu...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Glob Health Med
Main Authors: Yamada, Yasuhide, Muro, Kei, Takahashi, Keiichi, Baba, Hideo, Komatsu, Yoshito, Satoh, Taroh, Goto, Masahiro, Mishima, Hideyuki, Watanabe, Masahiko, Sakata, Yuh, Morita, Satoshi, Shimada, Yasuhiro, Takenaka, Naruhito, Hirooka, Tadashi, Sugihara, Kenichi
Format: Artigo
Jezik:Inglês
Izdano: National Center for Global Health and Medicine 2020
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731258/
https://ncbi.nlm.nih.gov/pubmed/33330814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.35772/ghm.2020.01050
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki